AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

April 14, 2021 GMT

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Apr 14, 2021--

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107 (International) and enter Conference ID 1191891. A replay will be archived on the company’s website following completion of the call.

ADVERTISEMENT

About Glaukos

Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent ®, its first MIGS device, in the United States in 2012, its next-generation iStent inject ® device in the United States in 2018, and most recently, the iStent inject W device in October 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210414005698/en/

CONTACT: Chris Lewis

Sr. Director, Investor Relations, Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH PHARMACEUTICAL OPTICAL

SOURCE: Glaukos Corporation

Copyright Business Wire 2021.

PUB: 04/14/2021 04:15 PM/DISC: 04/14/2021 04:15 PM

http://www.businesswire.com/news/home/20210414005698/en